ABSTRACT

The present work is a descriptive study about functional and tomographic characteristics in patients with collagen vascular diseases (CVD). Pulmonary injury and hypoxemia used to be very frequent in these cases and is the trigger factor of the pulmonary hypertension (PH). At the present time exists few papers on PH associated with CVD-related interstitial lung disease. Our study shows a very high frequency of pulmonary alterations and hypoxemia in these patients. The new drugs and their impact in PH and eventual worsening in the V/Q relation is not evaluated clearly in this subgroup of patients.

KEYWORDS

Pulmonary hypertension, collagen vascular disease, interstitial lung disease, bronchiectasies.

REFERENCES

1. Battle, RW, Davitt, MA, Cooper, SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110: 1515-1519.

2. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.

3. Wigley FM, Mayes M, Limia JAC, McLain DA, Chapin L, Ward-Able C. The point prevalence of undiagnosed pulmonary hypertension (PAH) in patients with connective tissue disease (CTD) attending community based rheumatology clinics (UNCOVER study). Program and abstracts of the American College of Rheumatology 68th Annual Scientific Meeting; October 16-21, 2004; San Antonio, Texas. 1057.

4. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18: 147-151.

5. McLaughlin V, Presberg K, Doyle R, Abman S, McCrory D, Fortin T, Ahear G. Prognosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest 126: 78S-92S.

6. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl S: 5S-12S.

7. Presberg K, Dincer E. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med 2003; 9: 1-12.

8. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; Suplement, 126(1).

9. Marc H, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351(14): 1425-1436.

10. Badesch D, Tapson V, Mc Goon M., Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000; 132: 425-434.